Literature DB >> 29305086

The Candidate Schizophrenia Risk Gene DGCR2 Regulates Early Steps of Corticogenesis.

Aude Molinard-Chenu1, Alexandre Dayer2.   

Abstract

BACKGROUND: Alterations in early steps of cortical circuit assembly are thought to play a critical role in vulnerability to schizophrenia (SZ), but the pathogenic impact of SZ-risk mutations on corticogenesis remains to be determined. DiGeorge syndrome critical region 2 (DGCR2) is located in the 22q11.2 locus, whose deletion is a major risk factor for SZ. Moreover, exome sequencing of individuals with idiopathic SZ identified a rare missense mutation in DGCR2, further suggesting that DGCR2 is involved in SZ.
METHODS: Here we investigated the function of Dgcr2 and the pathogenic impact of the SZ-risk DGCR2 mutation in mouse corticogenesis using in utero electroporation targeted to projection neurons.
RESULTS: Dgcr2 knockdown impaired radial locomotion and final translocation of projection neurons, leading to persistent laminar positioning alterations. The DGCR2 missense SZ-risk mutation had a pathogenic impact on projection neuron laminar allocation by reducing protein expression. Mechanistically, we identified Dgcr2 as a novel member of the Reelin complex, regulating the phosphorylation of Reelin-dependent substrates and the expression of Reelin-dependent transcriptional targets.
CONCLUSIONS: Overall, this study provides biological evidence that the SZ-risk gene DGCR2 regulates critical steps of early corticogenesis possibly through a Reelin-dependent mechanism. Additionally, we found that the SZ-risk mutation in DGCR2 has a pathogenic impact on cortical formation by reducing protein expression level, suggesting a functional role for DGCR2 haploinsufficiency in the 22q11.2 deletion syndrome.
Copyright © 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  22q11; Corticogenesis; DGCR2; Neuronal migration; Reelin; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 29305086     DOI: 10.1016/j.biopsych.2017.11.015

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  Transcriptomic underpinnings of high and low mirror aggression zebrafish behaviours.

Authors:  Florian Reichmann; Johannes Pilic; Slave Trajanoski; William H J Norton
Journal:  BMC Biol       Date:  2022-05-02       Impact factor: 7.364

2.  Positive psychotic symptoms are associated with divergent developmental trajectories of hippocampal volume during late adolescence in patients with 22q11DS.

Authors:  Valentina Mancini; Corrado Sandini; Maria C Padula; Daniela Zöller; Maude Schneider; Marie Schaer; Stephan Eliez
Journal:  Mol Psychiatry       Date:  2019-06-04       Impact factor: 15.992

3.  Application of CRISPR-Cas9 gene editing for congenital heart disease.

Authors:  Heeyoung Seok; Rui Deng; Douglas B Cowan; Da-Zhi Wang
Journal:  Clin Exp Pediatr       Date:  2021-03-02

4.  Modeling and Predicting Developmental Trajectories of Neuropsychiatric Dimensions Associated With Copy Number Variations.

Authors:  Noboru Hiroi; Takahira Yamauchi
Journal:  Int J Neuropsychopharmacol       Date:  2019-08-01       Impact factor: 5.176

Review 5.  In the line-up: deleted genes associated with DiGeorge/22q11.2 deletion syndrome: are they all suspects?

Authors:  Zahra Motahari; Sally Ann Moody; Thomas Michael Maynard; Anthony-Samuel LaMantia
Journal:  J Neurodev Disord       Date:  2019-06-07       Impact factor: 4.025

6.  MCF2 is linked to a complex perisylvian syndrome and affects cortical lamination.

Authors:  Aude Molinard-Chenu; Joël Fluss; Sacha Laurent; Méryle Laurent; Michel Guipponi; Alexandre G Dayer
Journal:  Ann Clin Transl Neurol       Date:  2019-12-17       Impact factor: 4.511

7.  Downregulation of the schizophrenia risk-gene Dgcr2 alters early microcircuit development in the mouse medial prefrontal cortex.

Authors:  Aude Molinard-Chenu; Michel Godel; Alicia Rey; Stefano Musardo; Timea Bodogan; Laszlo Vutskits; Camilla Bellone; Alexandre Dayer
Journal:  Int J Dev Neurosci       Date:  2022-03-11       Impact factor: 2.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.